Optimal Use of Immunomodulators and Biologics
|
|
- Jemima Gardner
- 6 years ago
- Views:
Transcription
1 3/17/214 Optimal Use of Immunomodulators and Biologics Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. Loftus Disclosures (last 12 months) Research support Abbott Labs UCB Pharma Bristol-Myers Squibb Shire Genentech Janssen Biotech Amgen Pfizer Braintree Labs Millennium-Takeda Santarus GlaxoSmithKline Robarts Clinical Trials Consultant Abbott Labs UCB Pharma Janssen Biotech Takeda 1
2 3/17/214 Overview Existing treatment paradigms Thiopurine Anti-TNF agents Evolving paradigms Role of AZA monotherapy? Treat earlier in the course of Crohn s Use objective evidence of inflammation to base treatment decisions Use objective evidence to follow up on treatment changes Use drug monitoring when available 21 MFMER slide-3 Existing Treatment Paradigms 21 MFMER slide-4 2
3 Induction Maint Patients (%) 3/17/214 Management of Mild to Moderate UC Oral 5-ASAs Mesalamine g/d Balsalazide 6.75 g/d Sulfasalazine 4 6 g/d ± Rectal 5-ASA 1 st -Line Extensive (pancolitis) Oral steroid IV steroid Infliximab, Adalimumab 2 nd - Line 3 rd -Line 5-ASA, AZA/6-MP, IFX/ADA Kornbluth A, Sachar D. Am J Gastroenterol 21;15: Ordas I, Eckmann L, et al. Lancet 212;38: Azathioprine for Steroid-Dependent, Active UC Steroid-Free Clinical/Endoscopic Remission After 6 Months 6 53% % P=.6 5-ASA 3.2 g per day (in 3 divided doses ) AZA 2 mg/kg/d Defined as clinical remission (Powell-Tuck Index Score of ) and endoscopic remission (Baron Index Score 1) plus steroid discontinuation. Patients treated with concurrent tapering dose of steroids..8 g at breakfast and lunch and 1.6 g at dinner. Ardizzone S et al. Gut 26;55: % AE rate in AZA group 6% had to discontinue AZA 3
4 Percent of Patients Percent of Patients 3/17/214 Infliximab for UC: ACT 1 and ACT 2 Clinical Remission Placebo IFX 5 mg/kg IFX 1 mg/kg Weeks 3 Weeks 54 Weeks P.2 vs placebo P.3 vs placebo P =.1 vs placebo ACT 1 ACT Placebo IFX 5 mg/kg IFX 1 mg/kg Weeks 3 Weeks Rutgeerts P et al. N Engl J Med 25;353: ACT1/2 Trials: Survival Free of Colectomy Sandborn WJ et al, Gastroenterology 29;137:
5 3/17/214 UC Success: AZA vs. IFX vs. AZA+IFX for Moderate to Severe UC: Week 16 9% 8% 7% 6% 5% 4% 3% 2% 1% 24% 22% 4% 5% 77% 69% 37% P <.5 vs AZA P<.5 vs AZA and vs IFX 63% 55% % Steroid-free Response Mucosal healing remission Conclusion: IFX+AZA superior to both AZA and IFX monotherapy in inducing steroid-free remission AZA IFX AZA + IFX Panaccione R et al, DDW 211 Oral Presentation #835. Cyclosporine vs. Infliximab for Acute Severe UC 11 patients steroid refractory UC Treatment failure No response day 7 No steroid-free remission day 98 Relapse between days 7 and 98 Colectomy Death SAE: CyA 16%, IFX 25% Conclusion: CyA was not superior to IFX in acute severe UC 8% 7% 6% 5% 4% 3% 2% 1% % Treatment Failure, % 54% Infliximab 6% Cyclosporine Laharie D, et al. Lancet 212;38:
6 3/17/214 Adalimumab for Moderate to Severe UC: Induction/Maintenance Trial (n=494) Week 8 Endpoints Week 52 Endpoints 6% 5% 4% 3% 2% 1% % 16.5% 9.3% 5.4% 41.1% 34.6% 31.7% Placebo ADA 6% 5% 4% 3% 2% 1% % 3.2% 25.% 17.3% 18.3% 15.4% 8.5% Placebo ADA Sandborn WJ et al, Gastroenterology 212;142: Golimumab (GLM) for Moderate to Severe Ulcerative Colitis, PURSUIT Studies Induction of Clinical Response Maintenance of Clinical Response Among Responders P <.1 vs placebo Sandborn WJ et al, Gastroenterology 213 (online early). Doi:1.153/j.gastro Sandborn WJ et al, Gastroenterology 213 (online early). Doi:1.153/j.gastro
7 Induction Maint 3/17/214 Management of Crohn s Disease Prednisone, Budesonide AZA/6MP/MTX Anti-TNF (Infliximab, Adalimumab, Certolizumab pegol Natalizumab AZA/MTX, Anti-TNF, Natalizumab Lichtenstein GR, Hanauer SB, Sandborn WJ. Am J Gastroenterol 29;14: Baumgart DC, Sandborn WJ. Lancet 212;38: Updated Meta-Analysis of AZA/6-MP for Crohn s Disease: Benefit Is Not So Clear Induction of Remission Prevention of Relapse Khan KJ et al, Am J Gastroenterol 211;16:
8 3/17/214 Methotrexate for Crohn s Disease Methotrexate 25 mg/week IM/SC (and possibly 15 mg/week orally) is effective for inducing remission in patients with steroiddependent and steroid-refractory active CD Methotrexate mg/week IM/SC is effective for maintenance of remission and steroid sparing in CD Less lymphomagenic than thiopurines? Construct of Biologic Agents Used in Crohn s Disease Murine Chimeric Humanized Human Recombinant Receptor/Fc Fusion Protein Pegylated Humanized Human D2E7 Infliximab IgG 1 isotype CDP571 Etanercept Natalizumab (p75) Onercept (p55) IgG 4 isotype CDP87 Certolizumab IgG 4 isotype Adalimumab IgG 1 isotype 75% human 95% human 1% human 95% human 1% human 8
9 % of Patients % of Patients % of Patients % of Patients % of Patients 3/17/214 Induction of Clinical Remission at Week 4 In Crohn s Disease: Certolizumab, Adalimumab, Infliximab 1 8 Certolizumab Certolizumab Pegol 1 Pegol 2 Adalimumab 3 Infliximab 4 6 NS NS n Tx Pbo CzP 4mg Pbo CzP 4 mg Pbo 1. Schreiber et al. Gastroenterology. 25 Sep;129(3): Sandborn et al. N Engl J Med 27 p<.5 3. Hanauer et al. Gastroenterology 26;13: NS Non-significance 4. Targan et al. N Engl J Med 1997;337: ADA 8/4m g ADA 16/8 mg Pbo INF 5mg/kg Delta INF 1mg/k g Net Remission at Six Months: Certolizumab, Adalimumab, Infliximab Certolizumab Pegol PRECISE Open-label Induction Week 6 Pbo 28.6 CzP 47.9 Week 26 remission Net remission week Infliximab ACCENT I Open-label Induction Week 2 Pbo 21. IFX 39. Week 3 remission Net remission week Certolizumab Pegol PRECISE 1 4 Pbo CzP Net remission week Adalimumab - CHARM Open Label Induction Week 4 Pbo 17. ADA 4. Week 26 remission Net remission week Schreiber et al. New Engl J Med 27;357: Hanauer et al. Lancet 22;359: Colombel et al. Gastroenterology 27;132: Sandborn et al. New Engl J Med 27;357:
10 Patients (%) 3/17/214 Mucosal Healing With Adalimumab in CD (EXTEND) P=.56, NS 27.4% ADA induction (16/8 mg)/placebo ADA QOW (4 mg) P< % 2 1 ITT, intent-to-treat; NS, not significant 13.1% 8/61 17/62 /61 15/62 Week 12 ITT Week 52 ITT Primary End Point Rutgeerts P et al. Gastroenterology 212;142:112. Natalizumab (Anti-Alpha 4 Integrin) Therapy for Crohn s Disease Monoclonal antibody to alpha 4 integrin Target molecules are VCAM-1 and MAdCAM-1 Blocks lymphocyte trafficking from vascular space to tissues Effective for induction and maintenance of response and remission and steroid-sparing Villablanca EJ et al, Gastroenterology 211;14:
11 Percent 3/17/214 ENACT-2 Natalizumab in Active Crohn s Disease: Maintenance of Clinical Response (7 points) in Week 12 Responders Placebo Natalizumab 1 At Week 36 At Week 6 At Week 36 At Week 6 P.1 Response Remission Sandborn WJ et al, N Engl J Med 25; 353: Natalizumab-Related Progressive Multifocal Leukoencephalopathy Reactivation of the human JC polyoma virus Severe neurologic disability or death Has occurred in 395 patients out of approximately 118,1 treated as of August 213 All but two cases occurred in MS patients (less than 2% of natalizumab use in US is for Crohn s) FDA mandated risk management program (TOUCH) Risk stratified by JC virus serology Use restricted to patients who have failed anti-tnf therapy Must be administered as monotherapy (without other immunosuppressive agents) Communication with Biogen Idec Pharmaceuticals, 213 Kleinschmidt-DeMasters BK et al, J Neuropathol Exp Neurol 212;7:
12 Steroid-Free Remission, % 3/17/214 Evolving Treatment Paradigms Diminishing Role of Thiopurine Monotherapy? 21 MFMER slide-23 AZA Is No Better Than Placebo For Early Crohn s Disease Prospective multicenter Spanish double-blind placebo-controlled trial (n = 131) Early Crohn s (<8 weeks) with active inflammation on endoscopy or MRE Primary endpoint: steroid-free remission at 76 weeks Steroids tapered by 1 mg/week till 2 mg and then 5 mg/week SAE: AZA, 2.6% vs 11.1% in placebo group p =.48 Panes J et al, Gastroenterology 213;145: MFMER slide-24 12
13 3/17/214 AZA vs Conventional Management for Early Crohn s Disease: GETAID Prospective multicenter French randomized open-label trial (n=132) Early Crohn s (<6 mo) with risk factors for disabling disease : age<4, perianal disease, steroids within 3 months of diagnosis AZA 2.5 mg/kg/day vs conventional rx (give AZA only for steroid dependency, chronic active disease with flares, poor steroid response, or severe perianal disease) Primary endpoint: %trimesters in steroid-free and anti-tnf-free remission over next 3 years Primary endpoints: AZA 67% vs. conventional management 56% (p=.69) No difference in need for surgery or steroids or anti-tnf therapy Cosnes J et al, Gastroenterology 213;145: MFMER slide-25 Evolving Treatment Paradigms Treat Earlier in the Course of Crohn s Disease 21 MFMER slide-26 13
14 (%) Proportion of Patients (%) 3/17/214 Top-Down vs Step-Up: Early Infliximab or Standard Therapy Clinical remission (CDAI <15), off corticosteroids, and no intestinal resection P.1 P=.6 P=.28 P=.797 P= Step-Up Top-Down Wk 14 Wk 26 Wk 52 Wk 78 Wk 14 N=133 D Haens G et al. Lancet 28;371:66. SONIC: Corticosteroid-Free Clinical Remission at Week 26 Primary Endpoint 1 8 p=.9 p<.1 p= /17 75/169 96/169 AZA + placebo IFX + placebo IFX+ AZA Colombel JF, et al. N Engl J Med 21;362:
15 3/17/214 Evolving Treatment Paradigms Treatment Decisions Based on Objective Evidence 21 MFMER slide-29 CDAI Versus CDEIS During Treatment With Prednisolone Complete lack of correlation between CDAI (primarily symptom-based) and endoscopic inflammation Symptoms and signs of Crohn s are neither sensitive nor specific r =.13; p = NS Modigliani R et al, Gastroenterology 199;98:
16 3/17/214 Is It Really Loss of Response or Non- Response? Are Symptoms Due to IBD? Celiac disease Bacterial overgrowth Bile salt diarrhea Irritable bowel syndrome Hypersensitivity colitis Short bowel syndrome Carbohydrate malabsorption (lactose and fructose) Bacterial Overgrowth in Crohn s Disease (n=153) Hydrogen glucose breath test in symptomatic patients Increased stool frequency, increased flatulence or pain 25% had positive breath tests Risk factors Multiple resections Partial colonic resection Ileocolonic disease Klaus J et al, BMC Gastroenterol 29;9:61 16
17 Proportion of Patients (%) 3/17/214 The Intersection Between Disease Assessment and Application of Therapy: SONIC: Corticosteroid-Free Clinical Remission at Week 26 by Baseline Endoscopy Status p<.1 p=.3 p= p=.927 p=.372 p= p=.3 p= p= /115 5/99 68/111 11/27 12/36 12/3 6/28 16/28 13/34 Lesions (n=325) No Lesions (n=93) No Endoscopy or UTD (n=9) AZA + placebo (n=17) IFX + placebo (n=169) IFX + AZA (n=169) Unable to determine Colombel JF, et al. N Engl J Med 21;362: Paradigm Shift for Making Treatment Decisions in Patients with Inflammatory Bowel Disease OLD: Treat based on symptoms But: symptoms are insensitive and non-specific for bowel inflammation NEW: Treat based on objective markers of inflammation Serologic (CRP reduction) Endoscopic (mucosal healing) Radiographic (CTE/MRE improvement) Goal should be mucosal healing or absence/reduction in inflammation This will be the only way we can hope to alter the natural history of Crohn s disease 17
18 Proportion of CD Patients Not Resected 3/17/214 Evolving Treatment Paradigms Treatment Endpoint Based on Objective Evidence Not Symptoms 21 MFMER slide-35 Mucosal Healing After Treatment as Predictor of Subsequent Disease Course in Crohn s Disease: Norway 1. Patients with MH at 1 year Patients without MH at 1 year Time in Years After 1-Year Visit MH, mucosal healing Frøslie KF et al. Gastroenterology. 27;133:
19 Patients (%) Median CRP (mg/l) Patients In Remission (%) 3/17/214 Steroid Avoidance Had More Endoscopic Healing at 2 Years Secondary End Point of the Top-Down/Step-Up Trial P= Step-up Top-down Complete endoscopic healing at 2 years and these patients did better in the next 2 yrs! 7.8 Remission Off Steroids Simple endoscopic score 1 9 Simple endoscopic score Off Steroids, No Anti-TNF D Haens G, et al. Lancet 28;371:66. Baert FJ, et al. Gastroenterology 21;138:463. Levels of CRP Are Associated With Mucosal Healing Retrospective analysis of clinical and endoscopic outcomes from serial CRP measurements in 718 CD patients receiving infliximab P=.3 P= No Healing Partial Healing Complete Healing Jurgens M et al. Clin Gastroenterol Hepatol 211;9:
20 3/17/214 CT Enterography Healing: Equivalent to Mucosal Healing at Endoscopy? 3/25/25 1/11/26 Resolution of intramural inflammation on maintenance infliximab Bruining DH, et al. Clin Gastroenterol Hepatol 211;9: Radiographic Improvement on MR Enterography Correlates With Endoscopic Improvement: Δ MaRIA- Δ CDEIS at Week 12 r =.61 p <.1 Ordas I, et al. Gastroenterology 211;14(5 Suppl 1):S73 (DDW 211). Courtesy of Ingrid Ordas, M.D. 2
21 3/17/214 Implementing Treat to Target in IBD: Mucosal Healing as the Target Primary target: absence of mucosal ulceration Level of target may be influenced by comorbidities and drug-related risks Desired target should be maintained indefinitely Use both symptoms and objective measures of inflammation (endoscopic or radiologic) to guide treatment decisions Assess mucosal healing every 6 months till target is achieved, then every 1-2 years after, adjust according to degree of inflammation Bouguen G, et al. Clin Gastroenterol Hepatol 213 (online early). Doi:1.116/j.cgh Baseline assessment of disease activity by endoscopy paired with surrogate marker A Proposed Algorithm for Disease Monitoring in IBD Choice of initial therapy based on severity and prognosis of patient 3-6 months Re-assessment of disease activity directly or with surrogate marker No Healing Documented? Yes 6-12 months Discussion with patient treatment options Clinical follow-up that includes assessment of disease stability Clinical follow-up No If no other treatment options left Is patient willing to proceed with your recommendations? Adjust therapy Yes Slide compliments of David T. Rubin, MD 3-6 months 21
22 3/17/214 Challenges to Mucosal Healing in Crohn s Disease It can t be achieved in many/most patients Unclear how much healing is really needed to affect outcomes It is unknown what incremental healing can be achieved by dose escalation or switching therapies We don t know the appropriate time interval between changes in therapy and subsequent reassessment Can surrogates of endoscopic healing be used? Evolving Treatment Paradigms Therapeutic Drug Monitoring 21 MFMER slide-44 22
23 Frequency of Response 3/17/214 TPMT Activity in 47 New Zealand Patients Wild type Homozygous mutation Heterozygous mutation Sies C et al. NZ Med J 25;118(121): Target 6-TGN Level to Optimize Efficacy: >235 P<.1 1% 8% 78% 6% 4% 2% 41% Odds Ratio 5. for treatment response when 6-TGN > 235 % n= n= n= TGN QUARTILES n= Dubinsky MC, et al. Gastroenterology 2;118(4):
24 3/17/214 Meta-Analysis: Association Between 6-TGN Levels and Clinical Remission Author & Year Patients (Remission) 6TGN Threshold Fraction Above Threshold Remission Fraction Below Threshold Remission Odds Ratio 95% Confidence Interval Dubinsky 2 92 (3) Gupta (47) Belaiche (19) Cuffari (47) Goldenberg (15) Achkar 24 6 (24) Pooled Estimate.62 (.43-.8).36 ( ) Osterman MT, et al. Gastroenterology 26:13(4); Suboptimal 6-TGN Production Correlates With 6-MP Resistance Median change in 6-TGN p= Median change in 6-MMP p= Non-Responders Responders Non-Responders Responders N=37 N=14 N=37 N=14 Dubinsky MC et al, Gastroenterology 22;122(4):
25 % of patients 3/17/214 Allopurinol Therapy for Preferential 6-MMP Metabolism Pre-allopurinol Post-allopurinol TG 6-MMP Allopurinol 1 mg added; 6-MP/AZA dose reduced to 25% to 5% of baseline Sparrow MP, et al. Aliment Pharmacol Ther 25;22:441. Detectable Serum Trough IFX Concentration is Associated with Higher Remission Rate and Endoscopic Improvement in UC Patients Remission Endoscopic Improv. P< Undetectable Detectable Undetectable serum IFX predicted an increased risk for colectomy (55% vs 7%; p<.1) Seow CH, et al. Gut 21;59:
26 Patients with Sustained Clinical Response (%) 3/17/214 ADA Trough Above.33 µg/ml Predicts Clinical Response Log Rank: P=.1 ADA TR>.33 µg/ml, n=14 ADA TR<.33 µg/ml, n= Sustained Clinical Response (weeks) Karmiris K, et al. Gastroenterology. 29;137:1628. Factors Affecting the Pharmacokinetics of Monoclonal Antibodies Presence of ADAs Concomitant use of IS High baseline TNF-α Low albumin High baseline CRP Body size Gender Impact on Pharmacokinetics Decreases serum mabs Threefold-increased clearance Worse clinical outcomes Reduces formation Increases serum mabs Decreases mab clearance Better clinical outcomes May decrease mabs by increasing clearance Increases clearance Worse clinical outcomes Increases clearance High BMI may increase clearance Males have higher clearance mab, monoclonal antibody; ADA, antidrug antibody Ordas I, et al. Clin Pharmacol Ther 212;91:
27 3/17/214 Elevating Infliximab Concentration From Subtherapeutic Levels Is Effective in Regaining Response in HACA (-) Patients Clinical Outcomes of Patients with Detectable Antibodies to Infliximab or Subtherapeutic Infliximab Concentrations Complete/ Response to Test Partial Response (%) P value Detectable HACA Subtherapeutic concentration Increase infliximab Change anti-tnf 11/12 (92) Increase infliximab Change anti-tnf 2/6 (33) 1/6 (17) <.4 25/29 (86) <.16 HACA, human antichimeric antibody Afif W et al. Am J Gastroenterol 21;15:1133. Conclusions AZA, 6-MP and MTX are steroid-sparing agents Anti-TNF agents are effective for inducing and maintaining response/remission in Crohn s (IFX, ADA, CZP) and UC (IFX, ADA, GLM) Anti-TNF agents can reduce the need for hospitalizations and surgeries in Crohn s and UC Natalizumab is an option for Crohn s disease patients who are anti-tnf refractory, but carries a risk of PML 27
28 3/17/214 Conclusions Several new studies suggest that azathioprine therapy may not be effective as we once thought Still has an important role in improving efficacy of anti-tnf therapy Use objective markers of inflammation rather than symptoms to make treatment decisions Follow up on changes in therapy with objective markers of inflammation Use drug monitoring when available 28
September 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationOptimizing Immunomodulators and
Optimizing Immunomodulators and Biologics i in Inflammatory Bowel Disease Sunanda Kane, MD, MSPH, FACG Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota,
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationOPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG
1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationAvailable Data on Pediatric Exposure Response a Clinician s Perspective
Available Data on Pediatric Exposure Response a Clinician s Perspective Marla Dubinsky, MD Professor of Pediatrics and Medicine Chief Pediatric GI and Nutrition Co-Director Susan and Leonard Feinstein
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationIl ruolo degli anticorpi anti farmaco nella pratica clinica
Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring
More informationEmerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
More informationTherapy for Inflammatory Bowel Disease
Therapy for Inflammatory Bowel Disease Jonathan P. Terdiman, MD Professor of Clinical Medicine Clinical Director, Center for Colitis and Crohn s Disease University of California San Francisco, CA UC: Current
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationTNF Inhibitors: Lessons From Immunogenicity
TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research:
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationDrug Level Monitoring in IBD. Objectives
Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug
More informationCrohn s
Crohn s Disease David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology, and Nutrition Co-Director, Digestive Diseases Center @IBDMD Disclosures
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationManagement of Refractory Crohn s Disease
Management of Refractory Crohn s Disease @IBDMD David T. Rubin, MD, FACG, FASGE Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Disclosures Consultant
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationThe evaluation and treatment of patients with Crohn s
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:395 399 PERSPECTIVE Do Not Assume Symptoms Indicate Failure of Anti Tumor Necrosis Factor Therapy in Crohn s Disease DAVID H. BRUINING* and WILLIAM J. SANDBORN
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationLatest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationBiologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases
Biologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases Walter Reinisch Univ-Klinik für Innere Medizin III Abt. Gastroenterologie & Hepatologie AKH Wien The Biologic s evolution From availabilitydriven
More informationWhen can I stop taking my medications? Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida
When can I stop taking my medications? Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Post-op low risk patient Uc de-escalation Discuss combo therapy Which one worked IBD
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationBiologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA
Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationAnti tumor necrosis factor (TNF) agents have
Achieving Clinical Response and Remission in Moderate-to-Severe Ulcerative Colitis With Golimumab Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical
More informationInflammatory Bowel Disease Drug Therapy 2016
Inflammatory Bowel Disease Drug Therapy 206 David T. Rubin, MD, FACG Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Objectives Outline the goals of
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationOptimizing the treatment of IBD through use of therapeutic drug monitoring
Optimizing the treatment of IBD through use of therapeutic drug monitoring Adam S. Cheifetz Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center Associate Professor of
More informationProgress in Inflammatory Bowel Disease
Progress in Inflammatory Bowel Disease Gary R Lichtenstein, MD Director, Center for IBD University of Pennsylvania School of Medicine Hospital of the University of PA Philadelphia, PA Disclosure Research,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationBiologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationEdward V. Loftus, Jr., M.D.
Edward V. Loftus, Jr., M.D. Professor of Medicine Faculty photo will be placed here loftus.edward@mayo.edu 2015 MFMER 3417200-1 Inflammatory Bowel Disease Therapy Edward V. Loftus, Jr., M.D. Gastroenterology
More informationAnti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis
Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis University, 1st Department of Medicine Budapest June 13-15,
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More information2nd Nottingham IBD Masterclass, 2017
2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory
More informationManagement of Moderate to Severe Ulcerative Colitis
Management of Moderate to Severe Ulcerative Colitis Neilanjan Nandi, MD Assistant Professor of Medicine Associate Program Director Division of Gastroenterology Drexel University College of Medicine Hahnemann
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationManaging Complications of IBD and Its Therapies David T. Rubin, MD, AGAF
Managing Complications of IBD and Its Therapies David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Medicine
More informationTherapeutic Drug Monitoring και ΙΦΝΕ το 2018
Therapeutic Drug Monitoring και ΙΦΝΕ το 2018 TDM: Ναι το χρειαζόμαστε, σε όλους και πάντοτε Κωνσταντίνος Κατσάνος Conflict of interest By means of this, the speaker confirms that he receives honoraria
More informationPharmacy Management Drug Policy
SUBJECT: Multiple Sclerosis, Crohn s Disease POLICY NUMBER: PHARMACY-53 EFFECTIVE DATE: 4/08 LAST REVIEW DATE: 12/18/2018 If the member s subscriber contract excludes coverage for a specific service or
More informationAchieving Success in Ulcerative Colitis: the Role of Infliximab
Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Francis A. Farraye, MD, MSc, FACG Professor of Medicine Clinical Director, Section of Gastroenterology Boston University School of Medicine Boston,
More informationTumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review)
Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review) Behm BW, Bickston SJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More informationAnti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients
Alimentary Pharmacology and Therapeutics Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients A. B. Mohabbat*, W. J. Sandborn, E. V. Loftus Jr, R. H. Wiesner
More informationCarefirst.+.V Family of health care plans
Carefirst.+.V Family of health care plans CVS care mark POLICY Document for ENTYVIO The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific
More informationINFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL A. Hillary Steinhart, MD MSc FRCP(C) Medical Lead, Mount Sinai Hospital IBD Centre Professor of Medicine University
More informationNew Perspectives on the Diagnosis and Management of IBD. Disclosures
New Perspectives on the Diagnosis and Management of IBD Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children's Hospital/Atlantic Health Professor of Pediatrics Icahn School of Medicine
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More information